TL/DR –
The first Indian edition of “PharmiCON” was held in Hyderabad, focusing on the expansion of Indian manufacturing to the United States. The event, hosted by the Confederation of Indian Industry (CII) Telangana and U.S.-based firm ICON, addressed the importance of resilience and global competitiveness for Indian companies amidst shifting regulations. A whitepaper titled “Changing Landscape: Indian Pharma’s Move Towards U.S.-Based Manufacturing” was also launched at the event, exploring how new U.S. policies are creating both constraints and opportunities for Indian companies.
“`html
Pharmaceutical leaders, policymakers, and investors gathered at the ICON-CII event in Hyderabad to discuss the opportunities and challenges of extending Indian manufacturing to the United States.
The inauguration of the first “PharmiCON” in India
The Confederation of Indian Industry (CII) Telangana and ICON, a U.S.-based construction and project delivery company, hosted the first Indian version of “PharmiCON” in Hyderabad. The meet-up centered on the theme “Navigating the Road Ahead for U.S.-Based Manufacturing,” highlighting the strategic shift of Indian pharma and its increasing focus on building capabilities for the global markets, with a specific focus on the U.S.
In their introductory remarks, CII Telangana Past Chairman Mr. Sanjay Singh and CII Pharma and Life Sciences Panel Convener Mr. Chakravarthi AVPS underscored the necessity of resilience and global competitiveness as Indian businesses grapple with changing regulations and increased demands from international regulatory bodies and partners.
ICON’s impressive portfolio and Telangana’s global-scale pharma and medtech innovation
ICON’s CEO and Founder Mr. Bhupendra Patel shed light on the company’s vast experience in building pharmaceutical and biopharma facilities in the U.S. Patel noted that ICON has completed projects worth over $300 million, covering more than 200 locations and over 1 million square feet of built space. ICON offers a complete package of services ranging from land purchase to design, execution, and operational turnover for Indian pharma and biotech firms aiming to establish or expand their presence in the U.S. market.
The Telangana government’s involvement was represented by Mr. Venugopal Rao Sankineni, Vice President for Medical Devices (Policy & Investments) at Telangana Lifesciences, who pitched the state as a pioneering catalyst for pharma and medtech innovation on a global scale.
New policy changes influencing the Indian Pharma industry
A whitepaper co-written by ICON and CII and partnered by Healthark, titled “Changing Landscape: Indian Pharma’s Move Towards U.S.-Based Manufacturing,” was unveiled at the event. The document delves into how new U.S. policies, such as the Inflation Reduction Act and the BIOSECURE Act, are presenting both hindrances and prospects for Indian companies, specifically in areas like biologics, injectables, and contract manufacturing.
Panel discussions and concluding remarks
The conference included two panel discussions addressing the key elements guiding this evolution: the first discussion concentrated on the logistics, incentives, and risks associated with U.S.-based operations, while the second discussion explored the recalibration of the global supply chain in light of recent geopolitical shifts.
Summing up the event, Mr. Chakravarthi AVPS stressed that the Indian pharmaceutical industry is at a crucial juncture, and timely international investment, particularly in U.S. manufacturing, could boost its long-term credibility, capacity, and global stature in the life sciences field.
Follow Prittle Prattle News for more important stories, led by our Editor-in-Chief Smruti Bhalerao, as we are committed to broadcasting powerful narratives that promote awareness and inspire change. Connect with us on LinkedIn, Instagram, and YouTube.
“`
—
Read More US Economic News